Psychiatry and Psychology

Below are current clinical trials.

39 studies in Psychiatry and Psychology
(open studies only).

Filter this list of studies by location, status and more.

1. A Study to Evaluate a Primary Care-Based Intervention for Adolescent Restrictive Eating Disorders

   Rochester, Minn.

   The purpose of this study is to assess the feasibility, acceptability, usability, and preliminary outcomes of a treatment protocol (FBT-PC) for PCP management of adolescent restrictive eating disorders.

2. A Study to Evaluate Smartphone-based Digital Phenotyping for Relapse Prediction in Alcohol-associated Liver Disease

   Rochester, Minn.

   The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients with alcohol-associated liver disease.

   The secondary aim of this study is to assess the relationship between this digital phenotype and markers of disease severity outcome, including MELD score and readmission rates.

3. Acamprosate Treatment Outcome

   Rochester, Minn., Albert Lea, Minn.

   The purpose of this project is to identify biomarkers by discovery of genomic and metabolomic markers associated with response to acamprosate treatment. To achieve this we will use “pharmacometabolomics-informed pharmacogenomics” such as generation a panel of iPSCs (stem cells) to discover biomarkers.  A new prospective randomized placebo-controlled trial of 3 month long treatment with acamprosate/placebo will provide new biospecimens, in addition to previously collected biospecimens, to enable the search for genetic and metabolomic biomarkers associated with sobriety or relapse in participants of this new study.

4. Augmented Human Intelligence in Major Depressive Disorder

   Rochester, Minn., Jacksonville, Fla.

   The primary purpose of this study is to evaluate the degree of statistical agreement between observed clinical outcomes (non-response/remission) after 8 weeks of treatment and the outcomes predicted by an Augmented Human Intelligence (AHI)-based clinical decision support tool after 2 weeks of follow up.

5. A Study to Evaluate Cancer Distress, Psychological Trauma, and Resiliency in Hospitalized Hematopoietic Stem Cell Transplant Patients

   Jacksonville, Fla.

   The purpose of this study is to better understand the distress experience of hospitalized patients undergoing hematopoietic stem cell transplant (HSCT), and to examine the relationship between cancer distress, psychological trauma, and resiliency over time.

6. Chronic Pain Biobank

   Jacksonville, Fla.

   The purpose of this study is to create a biorepository for samples of chronic pain patients.

7. Advanced Care Planning in Dementia

   Jacksonville, Fla.

   The goal of this study is to gain a better understanding of the status of advanced care planning among caregivers of patients with dementia and examine how this differs by race and disease stage.

8. A Study of Cognitive Behavioral Cancer Stress Management (CBCSM) and its Effects on Cancer Distress

   Rochester, Minn.

   The purpose of this study is to test the effectiveness of cancer stress management (CBCSM) as a clinical service at Mayo Clinic.

9. A Study Evaluating the Prevalence, Incidence and Predictors for Development of the Impulse Control Disorders in Patients with Prolactinomas Treated with Dopamine Agonist Therapy

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to establish incidence and prevalence of Impulse Control Disorders (ICDs) in patients with prolactinomas treated with dopamine agonists (DA), to determine the predictors of ICD development, and to establish a predictor scoring system that could be subsequently validated and applied prior to initiation of DA.

10. A Study of Dihydropyrimidine Dehydrogenase Function in Neural Development and Function

    Rochester, Minn.

    The purpose of this study is to obtain punch biopsies obtained from individuals with intellectual disability (ID) associated with dihydropyrimidine dehydrogenase (DPD) deficiency and unaffected related controls (e.g., biological parents and/or siblings), to derive patient-specific reprogrammed cells, characterize reprogrammed cells and differentiated neural tissues by comparing molecular genetics and cellular phenotypes through comprehensive gene expression profiles, proteomic analysis, metabolic measurements, and physical measurements, and determine if changes in neural differentiation and/or function can be ameliorated through correction of DPD deficiency, enzyme replacement therapy, or treatment with other compounds.